B Braun of Germany buys plant in Russia
This article was originally published in Scrip
B Braun, the German privately-owned provider of pharmaceuticals and medical goods including infusion and electrolyte solutions, has acquired Gematek in Tver, 170 km north-east of Moscow, from IFD Kapital, a Russian investment firm. Gematek was initially IFD Kapital's investment project to build a production facility for infusion solutions based on the latest technologies and standards. Financial details of the deal have not been released, but IFD Kapital said that its financial return exceeded almost twice its investments in the project; Russian experts estimate the deal was worth around $2 million. B Braun, which had been operating in Russia for a few years, believes the deal will strengthen its position on the local market and help to save funds currently spent on transportation of its products from Germany. The company has more than 27,000 employees in 140 subsidiaries in almost 50 countries.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.